

# Carlo Tondini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7485226/publications.pdf>

Version: 2024-02-01

118  
papers

5,796  
citations

117571

34  
h-index

79644

73  
g-index

121  
all docs

121  
docs citations

121  
times ranked

8276  
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . New England Journal of Medicine, 2014, 371, 497-506.	13.9	745
2	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine, 2014, 371, 107-118.	13.9	621
3	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 2018, 379, 122-137.	13.9	448
4	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1385-1393.	5.1	342
5	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
6	Histiocyte disorders. Critical Reviews in Oncology/Hematology, 2004, 50, 157-174.	2.0	152
7	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discovery, 2020, 10, 1465-1474.	7.7	151
8	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology, 2016, 34, 2221-2231.	0.8	148
9	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncology, The, 2015, 16, 848-858.	5.1	145
10	Adult acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 2004, 50, 197-222.	2.0	144
11	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Research and Treatment, 2012, 134, 283-289.	1.1	101
12	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of Clinical Oncology, 2016, 34, 1601-1610.	0.8	100
13	Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.. Journal of Clinical Oncology, 1993, 11, 720-725.	0.8	98
14	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Journal of Clinical Oncology, 2020, 38, 1293-1303.	0.8	93
15	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
16	Diffuse Large-Cell Lymphoma of the Testis. Journal of Clinical Oncology, 1999, 17, 2854-2854.	0.8	82
17	Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database. European Journal of Cancer, 2009, 45, 2537-2545.	1.3	82
18	Adult acute lymphoblastic leukaemia. Critical Reviews in Oncology/Hematology, 2004, 50, 223-261.	2.0	79

#	ARTICLE	IF	CITATIONS
19	Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. <i>Annals of Oncology</i> , 2010, 21, 871-876.	0.6	76
20	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754.	0.6	76
21	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
22	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	0.8	72
23	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	0.8	65
24	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	0.9	61
25	Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: The Milan Cancer Institute Experience. <i>Annals of Oncology</i> , 1993, 4, 831-837.	0.6	58
26	Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: A prospective randomised multicentre trial. <i>Breast</i> , 2009, 18, 373-377.	0.9	58
27	Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. <i>Annals of Oncology</i> , 2017, 28, 2225-2232.	0.6	56
28	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
29	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
30	Taxol administered as a 120 hour infusion. <i>Investigational New Drugs</i> , 1992, 10, 275-278.	1.2	48
31	Breast-Conservative Surgery With and Without Radiotherapy in Patients Aged 55-75 Years With Early-Stage Breast Cancer: A Prospective, Randomized, Multicenter Trial Analysis After 108 Months of Median Follow-up. <i>Annals of Surgical Oncology</i> , 2014, 21, 408-415.	0.7	44
32	Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 1999, 10, 1433-1440.	0.6	42
33	Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. <i>Breast</i> , 2011, 20, 176-183.	0.9	42
34	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 264-273.e2.	0.6	41
35	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	2.3	39
36	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	1.3	37

#	ARTICLE	IF	CITATIONS
37	Initial chemotherapy for primary resectable large-cell lymphoma of the stomach. <i>Annals of Oncology</i> , 1997, 8, 497-499.	0.6	36
38	PCR-based clonality analysis: a reliable method for the diagnosis and follow-up monitoring of conservatively treated gastric B-cell MALT lymphomas?. <i>Histopathology</i> , 1999, 34, 326-330.	1.6	34
39	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. <i>Human Mutation</i> , 2019, 40, e1-e23.	1.1	34
40	Supporting tools for guideline development and dissemination. <i>Artificial Intelligence in Medicine</i> , 1998, 14, 119-137.	3.8	33
41	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271.	0.5	33
42	Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study. <i>Annals of Oncology</i> , 2000, 11, 231-233.	0.6	32
43	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
44	Dose-escalation of CHOP in non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1999, 10, 519-526.	0.6	28
45	Association of Socioeconomic Status With Breslow Thickness and Disease-Free and Overall Survival in Stage I-II Primary Cutaneous Melanoma. <i>Mayo Clinic Proceedings</i> , 2011, 86, 113-119.	1.4	28
46	Circulating Tumor Markers in Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1989, 3, 653-674.	0.9	27
47	PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. <i>Genetics in Medicine</i> , 2014, 16, 688-694.	1.1	25
48	Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study. <i>BMJ Open</i> , 2017, 7, e014617.	0.8	25
49	Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1. <i>PLoS ONE</i> , 2014, 9, e86924.	1.1	24
50	Axillary recurrence in sentinel lymph node-negative breast cancer patients. <i>Annals of Oncology</i> , 2008, 19, 1842-1846.	0.6	23
51	Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. <i>European Journal of Cancer</i> , 2018, 95, 130-132.	1.3	23
52	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020, 105, 1704-1711.	1.7	21
53	Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996, 7, 970-972.	0.6	20
54	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 12-27.	2.0	19

#	ARTICLE	IF	CITATIONS
55	Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital. <i>Future Oncology</i> , 2014, 10, 233-239.	1.1	19
56	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReEnd trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	2.2	19
57	Prognostic impact of regression in patients with primary cutaneous melanoma &gt;1.5mm in thickness. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 99-105.e5.	0.6	19
58	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2220-2231.	1.9	17
59	Elevated CA125 levels in patients with metastatic breast carcinoma. <i>British Journal of Cancer</i> , 1990, 62, 668-670.	2.9	16
60	Adjuvant therapy in breast cancer and venous thromboembolism. <i>Thrombosis Research</i> , 2012, 130, S66-S70.	0.8	16
61	Axillary sentinel node biopsy under local anaesthesia in early breast cancer. <i>Annals of Oncology</i> , 2000, 11, 1617-1618.	0.6	15
62	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68.	2.0	15
63	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 503-503.	0.8	15
64	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	0.6	15
65	Surgical Resection Margins after Breast-Conserving Surgery: Senonetwork Recommendations. <i>Tumori</i> , 2016, 102, 284-289.	0.6	14
66	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2 <sup>-</sup> ) metastatic breast cancer (mBC) (TReEnd trial).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1002-1002.	0.8	14
67	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
68	Continuous Cisplatin Infusion in Combination with Vincristine and High-Dose Methotrexate for Advanced Osteogenic Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987, 10, 152-155.	0.6	13
69	START: A European state-of-the-art on-line instrument for clinical oncologists. <i>Annals of Oncology</i> , 1999, 10, 769-774.	0.6	13
70	Long-term evaluation of surgery followed by adjuvant adriamycin in osteogenic sarcoma. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 433-436.	0.9	12
71	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 121-129.	1.1	11
72	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 597-611.	3.3	11

#	ARTICLE	IF	CITATIONS
73	Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction. <i>Frontiers in Oncology</i> , 2018, 8, 480.	1.3	11
74	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
75	Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival. <i>Future Oncology</i> , 2019, 15, 967-977.	1.1	10
76	Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1254-1256.e4.	0.6	9
77	Breast cancer electron intraoperative radiotherapy: assessment of preoperative selection factors from a retrospective analysis of 758 patients and review of literature. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 261-271.	1.1	9
78	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , 2021, 05, e56-e65.	0.7	9
79	The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 579-588.	1.1	8
80	Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study. <i>Breast</i> , 2020, 52, 1-7.	0.9	8
81	Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. <i>Cancers</i> , 2021, 13, 532.	1.7	8
82	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 321-329.	1.1	7
83	Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic. <i>Oncologist</i> , 2021, 26, 341-347.	1.9	7
84	Abstract S5-06: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study. , 2013, . .		7
85	High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. <i>Cancer</i> , 1989, 64, 2014-2018.	2.0	5
86	The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model. <i>Tumori</i> , 2021, 107, 166-170.	0.6	5
87	Sentinel node biopsy in the surgical management of breast cancer: experience in a general hospital with a dedicated surgical team. <i>Breast</i> , 2004, 13, 200-205.	0.9	4
88	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
89	Pre-operative endocrine therapy for postmenopausal women: When and why?. <i>Annals of Oncology</i> , 2001, 12, 1505-1506.	0.6	3
90	Type and trends in outcomes research in breast cancer between 2000 and 2007. <i>Annals of Oncology</i> , 2011, 22, 2160-2165.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Abstract P4-21-42: MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results. , 2017, , .		3
92	Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 557-557.	0.8	3
93	Population-based sentinel lymph node biopsy in early invasive breast cancer. European Journal of Surgical Oncology, 2004, 30, 618-623.	0.5	2
94	Breast cancer follow-up: just a burden, or much more?. Annals of Oncology, 2007, 18, 1431-1432.	0.6	2
95	Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. , 2015, , .		2
96	Measurement of Thrombin Generation Is a Positive Predictive Biomarker of Venous Thromboembolism (VTE) in Metastatic Cancer Patients Enrolled in the Hypercan Study. Blood, 2015, 126, 654-654.	0.6	2
97	Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.. Journal of Clinical Oncology, 2011, 29, 516-516.	0.8	2
98	Hypercoagulation Screening As a Marker of Thrombosis and Poor Disease Prognosis in Cancer Patients: The Hypercan Prospective Study. Blood, 2014, 124, 586-586.	0.6	2
99	A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training&#x2014;Validation Trial. Journal of Medical Internet Research, 2022, 24, e27349.	2.1	2
100	Role of endosonography in the management of patients with gastric malt lymphoma. Gastroenterology, 1998, 114, A683.	0.6	1
101	Breast-Cancer Risk in Families With Mutations in PALB2. Obstetrical and Gynecological Survey, 2014, 69, 659-660.	0.2	1
102	1872 Moving beyond clinical trials: A real world multicenter Italian experience with albumin-bounded Paclitaxel (nab-Paclitaxel) in metastatic breast cancer. European Journal of Cancer, 2015, 51, S290.	1.3	1
103	Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience. Annals of Oncology, 2016, 27, iv9.	0.6	1
104	Prognostic factors in non-Hodgkin&#x2014;s lymphoma. Current Opinion in Oncology, 1990, 2, 849-854.	1.1	0
105	Lack of carboplatin activity in malignant lymphomas. European Journal of Cancer, 1996, 32, 2370-2371.	1.3	0
106	START programme. European Journal of Cancer, 1999, 35, S387.	1.3	0
107	Tailoring a tailored treatment: the importance of fine-tuning on the patient. Annals of Oncology, 2005, 16, 683-685.	0.6	0
108	Axillary recurrence in sentinel lymph node negative breast cancer patients. European Journal of Cancer, Supplement, 2008, 6, 150.	2.2	0



#	ARTICLE	IF	CITATIONS
109	9318 Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease free and overall survival in clinical stage I-II AJCC skin melanomaâ€“apro prospective study. European Journal of Cancer, Supplement, 2009, 7, 582.	2.2	0
110	PO62 DIFFERENT PATTERNS OF TREATMENT WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR TARGETED CHEMOTHERAPY IN METASTATIC BREAST CANCER: A MULTICENTER ITALIAN EXPERIENCE ON 125 WOMEN. Breast, 2013, 22, S41.	0.9	0
111	Prophylaxis strategy to prevent HBV-reactivation in oncologic immunosuppressed patients: Results of guidelines-based on-field practice. Digestive and Liver Disease, 2014, 46, e51.	0.4	0
112	P3.02c-092 Nivolumab in Multi-Treated Patients with Advanced Sq-NSCLC: Data from theÂltalian Cohort of Expanded Access Programme (EAP). Journal of Thoracic Oncology, 2017, 12, S1334-S1335.	0.5	0
113	PO-0850: Full-Dose Breast Intraoperative Radiotherapy In The Elderly: A Single Center Experience. Radiotherapy and Oncology, 2018, 127, S444-S445.	0.3	0
114	Relationship between socio-economic status and education grade on Breslow thickness and ulceration in clinical stage I-II AJCC skin melanoma: Analysis from a single institution prospectively collected data base.. Journal of Clinical Oncology, 2010, 28, e19004-e19004.	0.8	0
115	Abstract 134: Mutational landscape of breast cancers from PALB2 germline mutation carriers. , 2016, , .		0
116	Abstract P2-03-01: Mutational landscape of breast cancers from PALB2 germline mutation carriers. , 2017, , .		0
117	Abstract P2-09-05: 12 years' median follow up (MFLU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer. , 2017, , .		0
118	Abstract P4-22-17: Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access â€œBALLETTâ€“study. , 2017, , .		0